• Skip to main content
  • Skip to secondary menu
  • Skip to primary sidebar
  • Skip to secondary sidebar
  • Skip to footer

  • Opinion
  • Health IT
    • Behavioral Health
    • Care Coordination
    • EMR/EHR
    • Interoperability
    • Patient Engagement
    • Population Health Management
    • Revenue Cycle Management
    • Social Determinants of Health
  • Digital Health
    • AI
    • Blockchain
    • Precision Medicine
    • Telehealth
    • Wearables
  • Startups
  • M&A
  • Value-based Care
    • Accountable Care (ACOs)
    • Medicare Advantage
  • Life Sciences
  • Research

GLP-1

Mochi Health Launches Insurance-Based Plans, Expanding Access to Personalized Obesity Care with Behavioral Therapy

by Jasmine Pennic 05/27/2025 Leave a Comment

Mochi Health Launches Insurance-Based Plans, Expanding Access to Personalized Obesity Care with Behavioral Therapy

What You Should Know:  - Mochi Health, a physician-guided obesity care program, announced the launch of its new insurance-based plans.  - These expanded offerings are designed to provide more personalized treatment experiences for patients, placing a strong emphasis on comprehensive obesity care that spans all aspects of an individual's health.  - The new insurance-based plans are available as an optional upgrade to Mochi’s existing offerings. They provide patients with access
Read More

CheqUp and WeightWatchers to Enhance GLP-1 Weight Loss Journeys in UK with Integrated Support

by Jasmine Pennic 05/27/2025 Leave a Comment

CheqUp and WeightWatchers to Enhance GLP-1 Weight Loss Journeys in UK with Integrated Support

What You Should Know:  - CheqUp, one of the UK’s leading providers of GLP-1 based weight loss services, and WeightWatchers, the global leader in science-backed weight management announced a new partnership.  - The collaboration will combine the offerings of both organizations to benefit patients in the UK seeking sustainable weight loss through GLP-1 medication coupled with comprehensive behavioural support. A Holistic Approach to GLP-1 Supported Weight Loss The partnership aims
Read More

LifeMD Launches $299 Introductory Wegovy® Bundle for Self-Pay Patients in Collaboration with Novo Nordisk

by Jasmine Pennic 05/22/2025 Leave a Comment

LifeMD Launches $299 Introductory Wegovy® Bundle for Self-Pay Patients in Collaboration with Novo Nordisk

What You Should Know:  - LifeMD, Inc., a provider of virtual primary care services announced a limited-time $299 introductory bundle for new self-pay patients prescribed Wegovy® (semaglutide).  - The comprehensive package includes both the GLP-1 medication and access to LifeMD’s virtual weight management program. The initiative is part of LifeMD's collaboration with Novo Nordisk, announced last month, and leverages a recently completed integration with NovoCare® Pharmacy to offer
Read More

Vida Health Data Shows Obesity Success Beyond GLP-1 Medications

by Syed Hamza Sohail 05/20/2025 Leave a Comment

Vida Health Data Shows Obesity Success Beyond GLP-1 Medications

What You Should Know: -   Vida Health, a virtual, personalized obesity care provider that helps patients manage obesity and related conditions, today announced outcomes from its Clinical Obesity Management Program, which demonstrate that most patients do not require expensive GLP-1s to achieve sustainable, significant weight loss. -  Data from more than 18,000 participants demonstrates that Vida’s tailored treatment plans and commitment to responsible prescribing deliver better outcomes,
Read More

PGxAI Unveils AI-Driven Genetic Tool to Personalize GLP-1 Treatment

by Jasmine Pennic 04/23/2025 Leave a Comment

PGxAI Unveils AI-Driven Genetic Tool to Personalize GLP-1 Treatment

What You Should Know:  - PGxAI, a leader in AI-powered pharmacogenomics released a new report aimed at personalizing treatment regimens for patients taking semaglutide (commonly known by brand names Ozempic and Wegovy) and other widely used weight-management drugs.  - Utilizing advanced artificial intelligence models, the report analyzes patient-specific genetic data to identify and quantify genetic variants that impact drug efficacy and safety, finding that up to a third of
Read More

Wondr Health Launches GLP-1 Support For All Benefit Plans

by Jasmine Pennic 04/22/2025 Leave a Comment

Wondr Health Launches GLP-1 Support For All Benefit Plans

What You Should Know:  - Wondr Health, a leader in digital, evidence-based lifestyle support and behavior-change interventions for weight and obesity management, has announced expansions to its comprehensive metabolic health programs.  - These expansions aim to help employers prevent and manage common and expensive weight-related chronic health conditions, while also mitigating the financial risks associated with GLP-1 coverage. GLP-1 Support for all Benefit Plans Wondr
Read More

Eli Lilly’s Oral GLP-1 Shows Positive Trial Results for Type 2 Diabetes

by Jasmine Pennic 04/17/2025 Leave a Comment

Lilly's Oral GLP-1 Shows Positive Phase 3 Results for Type 2 Diabetes

What You Should Know:  - Eli Lilly and Company announced positive topline Phase 3 results from ACHIEVE-1, a study evaluating the safety and efficacy of orforglipron compared to placebo in adults with type 2 diabetes whose blood sugar was inadequately controlled through diet and exercise alone.  - Orforglipron stands out as the first oral small molecule glucagon-like peptide-1 (GLP-1) receptor agonist, taken without food and water restrictions, to successfully complete a Phase 3
Read More

Phenomix Sciences Launches Clinical Trial to Predict GLP-1 Response Using Precision Obesity Test

by Jasmine Pennic 04/08/2025 Leave a Comment

Phenomix Sciences Launches Clinical Trial to Predict GLP-1 Response Using Precision Obesity Test

What You Should Know:  - Phenomix Sciences (Phenomix), a commercial precision obesity medicine biotechnology company, today announced the initiation of its first prospective, placebo-controlled clinical study.  - The research will evaluate the MyPhenome™ test's ability to predict individual patient responses to semaglutide, a GLP-1-based therapy that has become a cornerstone in the treatment of obesity. First Prospective Clinical Study of Semaglutide Using MyPhenome™
Read More

Virta Health Cuts GLP-1 Use for Weight Loss Over 50%, Driving Cost Savings for Payers

by Jasmine Pennic 04/04/2025 Leave a Comment

Virta Health Cuts GLP-1 Use for Weight Loss Over 50%, Driving Cost Savings for Payers

What You Should Know:  - Virta Health, a leader in diabetes reversal and sustainable weight loss through its nutrition-first methodology, has announced early results from its recently launched Sustainable Weight Loss GLP-1 prescribing capabilities.  - These outcomes signal a potentially transformative shift in obesity and weight loss management, offering organizations a responsible framework for covering GLP-1 medications while actively reducing reliance and controlling overall
Read More

Collective Health, Noom Health Offer Integrated GLP-1 Weight Management Solution

by Jasmine Pennic 03/26/2025 Leave a Comment

Collective Health, Noom Health Offer Integrated GLP-1 Weight Management Solution

What You Should Know:  - Collective Health, a leader in employee health benefits, and Noom Health, the enterprise division of digital healthcare leader Noom announced a partnership to deliver Collective Health + Noom Med with SmartRx.  - The new program provides employers with an integrated weight management solution that includes a GLP-1 drug program, addressing the growing need for effective and affordable weight loss strategies. Addressing the Obesity Epidemic With
Read More

  • Go to page 1
  • Go to page 2
  • Go to page 3
  • Go to page 4
  • Next Page

Primary Sidebar

Subscribe to HIT Consultant

Latest insightful articles delivered straight to your inbox weekly.

Submit a Tip or Pitch

Featured Insights

2025 EMR Software Pricing Guide

2025 EMR Software Pricing Guide

Featured Interview

Paradigm Shift in Diabetes Care with Studio Clinics: Q&A with Reach7 Founder Chun Yong

Most-Read

Medtronic to Separate Diabetes Business into New Standalone Company

Medtronic to Separate Diabetes Business into New Standalone Company

White House, IBM Partner to Fight COVID-19 Using Supercomputers

HHS Sets Pricing Targets for Trump’s EO on Most-Favored-Nation Drug Pricing

23andMe to Mine Genetic Data for Drug Discovery

Regeneron to Acquire Key 23andMe Assets for $256M, Pledges Continuity of Consumer Genome Services

CureIS Healthcare Sues Epic: Alleges Anti-Competitive Practices & Trade Secret Theft

The Evolving Role of Physician Advisors: Bridging the Gap Between Clinicians and Administrators

The Evolving Physician Advisor: From UM to Value-Based Care & AI

UnitedHealth Group Names Stephen Hemsley CEO as Andrew Witty Steps Down

UnitedHealth CEO Andrew Witty Steps Down, Stephen Hemsley Returns as CEO

Omada Health Files for IPO

Omada Health Files for IPO

Blue Cross Blue Shield of Massachusetts Launches "CloseKnit" Virtual-First Primary Care Option

Blue Cross Blue Shield of Massachusetts Launches “CloseKnit” Virtual-First Primary Care Option

Osteoboost Launches First FDA-Cleared Prescription Wearable Nationwide to Combat Low Bone Density

Osteoboost Launches First FDA-Cleared Prescription Wearable Nationwide to Combat Low Bone Density

2019 MedTech Breakthrough Award Category Winners Announced

MedTech Breakthrough Announces 2025 MedTech Breakthrough Award Winners

Secondary Sidebar

Footer

Company

  • About Us
  • Advertise with Us
  • Reprints and Permissions
  • Submit An Op-Ed
  • Contact
  • Subscribe

Editorial Coverage

  • Opinion
  • Health IT
    • Care Coordination
    • EMR/EHR
    • Interoperability
    • Population Health Management
    • Revenue Cycle Management
  • Digital Health
    • Artificial Intelligence
    • Blockchain Tech
    • Precision Medicine
    • Telehealth
    • Wearables
  • Startups
  • Value-Based Care
    • Accountable Care
    • Medicare Advantage

Connect

Subscribe to HIT Consultant Media

Latest insightful articles delivered straight to your inbox weekly

Copyright © 2025. HIT Consultant Media. All Rights Reserved. Privacy Policy |